Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Outpatients with a diagnosis of vascular dementia according to the NINDS-AIREN International Workshop criteria or with a diagnosis of mixed dementia (possible Alzheimer's disease with cerebrovascular disease) according to the NINCDS-ADRDA criteria~* mild-to-moderate dementia (score of 10 - 25 on the Mini Mental Status Exam (MMSE) and ADAS-cog score of at least 12)~* having the opportunity to perform activities of daily living (such as dressing, bathing, etc), including patients living independently in residential homes for the elderly~* had onset of disease between ages 40 - 90~* have a consistent informant to accompany them on scheduled visits~Exclusion Criteria:~* Neurogenerative disorders such as Parkinson's disease~* cognitive impairment resulting from conditions such as acute cerebral trauma, cerebral damage due to a lack of oxygen, vitamin deficiency, infections such as meningitis or AIDS, significant endocrine or metabolic disease, mental retardation, or a brain tumor~* having significant psychiatric disease, active peptic ulcer, clinically significant liver, kidney or lung disorders, or heart disease~* history of epilepsy, convulsions, drug abuse or alcohol abuse~* females of child bearing potential without adequate contraception

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).